Abstract
Anacetrapib is a cholesteryl-ester-transfer-protein (CETP) inhibitor, a new class of experimental drugs in the treatment of primary hypercholesterolemia and dyslipidaemia associated with the metabolic syndrome. One of the major advantages of this agent is, apart from the significant decrease in LDL-C it produces a substantial increase in HDL-C. Phase I, II, and III clinical trials have shown that anacetrapib is safe alone or in combination with statins. However, longterm clinical trials are required in order to assess whether it reduces mortality in individuals at high-risk of cardiovascular disease.
Keywords: Anacetrapib, cholesteryl, ester, transfer-protein, inhibitor, Dyslipidemia, cardiovascular disease, cholesterol, blood pressure, plasma
Current Clinical Pharmacology
Title: Anacetrapib: A New Weapon Against Dyslipidemia
Volume: 6 Issue: 4
Author(s): Georgios Aperis, Christos Paliouras, Eirini Tsampikaki, Nikolaos Papakonstantinou and Polichronis Alivanis
Affiliation:
Keywords: Anacetrapib, cholesteryl, ester, transfer-protein, inhibitor, Dyslipidemia, cardiovascular disease, cholesterol, blood pressure, plasma
Abstract: Anacetrapib is a cholesteryl-ester-transfer-protein (CETP) inhibitor, a new class of experimental drugs in the treatment of primary hypercholesterolemia and dyslipidaemia associated with the metabolic syndrome. One of the major advantages of this agent is, apart from the significant decrease in LDL-C it produces a substantial increase in HDL-C. Phase I, II, and III clinical trials have shown that anacetrapib is safe alone or in combination with statins. However, longterm clinical trials are required in order to assess whether it reduces mortality in individuals at high-risk of cardiovascular disease.
Export Options
About this article
Cite this article as:
Aperis Georgios, Paliouras Christos, Tsampikaki Eirini, Papakonstantinou Nikolaos and Alivanis Polichronis, Anacetrapib: A New Weapon Against Dyslipidemia, Current Clinical Pharmacology 2011; 6 (4) . https://dx.doi.org/10.2174/157488411798375949
DOI https://dx.doi.org/10.2174/157488411798375949 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Risk Factors of Alzheimers Disease Among Iranian Population
Current Alzheimer Research Liver Enzymes: Potential Cardiovascular Risk Markers?
Current Pharmaceutical Design Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke
Current Drug Therapy Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias
Current Cardiology Reviews Pharmacogenetics of the Antiplatelet Effect of Aspirin
Current Pharmaceutical Design Editorial Nutritional Therapy in Metabolic Syndrome
Current Vascular Pharmacology Recent Patents in Autophagy and Immune Response
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot Topic: The Medicinal Chemistry of New Agents to Treat Obesity (Guest Editor: Jinhwa Lee)]
Current Topics in Medicinal Chemistry Apo A-1 Mimetic Peptides as Atheroprotective Agents in Murine Models
Current Drug Targets Endothelial Progenitor Cells as Potential Drug Targets
Current Drug Targets - Cardiovascular & Hematological Disorders Gender Differences in the Clinical Presentation of Heart Disease
Current Pharmaceutical Design 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry NMR in Metabolic Profiles of Neural Stem/Progenitor Cells: Current Status and Relevant Problems
Current Medical Imaging Lipases in Medicine: An Overview
Mini-Reviews in Medicinal Chemistry Association of Admission Leukocyte Count with Clinical Outcomes in Acute Ischemic Stroke Patients Undergoing Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator
Current Neurovascular Research Developments in Imaging Technologies Related to Hypertensive Cardiovascular Diseases
Current Pharmaceutical Design Pharmacotherapy of Obesity - Benefit, Bias and Hyperbole
Current Medicinal Chemistry Can Dietary Polyphenols Prevent the Formation of Toxic Compounds from Maillard Reaction?
Current Drug Metabolism Computer Aided Drug Design Studies in the Discovery of Secondary Metabolites Targeted Against Age-Related Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Recent Progress in Pharmacological Research of Antioxidants in Pathological Conditions: Cardiovascular Health
Recent Patents on Anti-Infective Drug Discovery